Congenital Adrenal Hyperplasia
New congenital adrenal hyperplasia research, summarized each month in plain language.
2026 so far: So far in 2026 (January to September), studies linked hydrocortisone delivery and timing (pump and modified-release) with lower hormone markers, alongside screening and genetic-testing updates aimed at fewer false positives and clearer CYP21A2 results. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Hydrocortisone schedules. More studies tested pumps and modified-release timing strategies.
- Heart and metabolism. More data linked CAH control with metabolic and BP outcomes.
- Newborn screening. Programs refined second-tier tests and context-based cutoffs.
- Easier monitoring. Multiple approaches aimed to standardize or simplify monitoring.
- Genetic clarity. Long-read sequencing repeatedly addressed hard-to-interpret CYP21A2 cases.
New
September 2026
- Bedtime hydrocortisone. In one small study, bedtime modified-release hydrocortisone lowered hormone markers.
- Screening cutoffs. Birth-weight cutoffs reduced false positive newborn CAH screens.
- 17-OHP blood test. Blood 17-OHP most consistently separated CAH from similar conditions.
- Long-read genetics. Long-read sequencing helped sort complex CAH gene changes.
August 2026
- Androgen markers. Birth control pills were followed by lower androgen-related markers.
- Renin and blood pressure. Very low renin was linked to higher predicted high blood pressure.
- CYP21A2 sequencing speed. Sequencing confirmed many CYP21A2 gene changes more quickly.
- Newborn screening timing. Earlier newborn screening was linked to fewer salt-wasting symptoms.
July 2026
- Morning hormone levels. Modified-release hydrocortisone lowered morning markers and slowed growth.
- Blood pressure and potassium. In 17 alpha-hydroxylase deficiency, steroids stabilized blood pressure and potassium.
- Stimulation test timing. A 60-minute blood draw found cases a 30-minute draw missed.
- Emotional and social strain. Studies again reported ongoing emotional and social strain.
June 2026
- Long-term health patterns. Health records showed more heart, metabolic, and bone conditions.
- Mailed hormone testing. Mailed dried blood spots measured key CAH hormones reliably.
- Confirming positive screens. Positive screens still needed confirmatory testing and follow-up.
May 2026
- Fewer false alarms in screening. Adding a second bloodspot test after the first screen reduced false-positive results while still detecting classical CAH.
- 21-deoxycortisone as a screening marker. 21-deoxycortisone looked accurate in stored samples, but it has not yet been proven in real-time newborn screening.
- Modified-release hydrocortisone in adults. In adults with classic CAH, modified-release hydrocortisone was linked to better insulin sensitivity.
- Emotional stress and crisis-like events. In a parent survey, many families linked emotional stress to suspected crisis-like episodes.
April 2026
- Slower dose reduction. Experts described a gradual approach to lowering steroid doses after starting crinecerfont.
- Hair cortisol monitoring. Hair cortisol may help track longer-term hydrocortisone exposure, but it is not yet proven.
- Newborn screening misses. In one pediatric cohort, newborn screening often did not flag children who were later diagnosed with non-classic CAH.
- Relationships and fertility. Interviews described ongoing effects of CAH on relationships, sexuality, and fertility.
March 2026
- More specific follow-up hormone tests. Using more specific hormone measurements in follow-up testing helped reduce false-positive CAH results.
- Newborn screening can still miss CAH. A case report showed that CAH can still be missed by standard newborn screening.
- Childhood weight rebound patterns. In a large registry dataset, earlier-than-usual weight rebound was common in children with CAH.
- Steroid dose tradeoffs. Some studies reported that stronger glucocorticoid regimens lowered androgen levels but were also linked with side effects such as weight gain and Cushingoid features in some people.
February 2026
- Saliva hormone tracking. In children with classic CAH, saliva hormone measurements often moved in the same direction as blood hormone levels, which could support less invasive monitoring if it can be used reliably in routine reporting.
- More consistent bone age reads. Automated bone age reading sometimes matched expert-style readings more closely than individual human readers, which could make bone age follow-up easier to compare over time.
- Recognizing CAH subtypes. Reports of rarer CAH subtypes described distinct hormone patterns and newly identified genetic changes, underscoring that CAH includes several related conditions rather than one single pattern.
- Blood pressure and daily function. In P450 oxidoreductase deficiency, higher blood pressure and more hypertension were reported than in matched controls, while separate child studies reported mixed results for school and developmental measures.
January 2026
- Hydrocortisone pump use. In a small group, pump dosing lowered hormone control markers.
- Newborn salt labs. Salt-balance labs often improved over 90 days, but not always.
- CYP21A2 DNA testing. Long-read DNA testing often clarified CYP21A2 results without parents.
Get the monthly update by email
Subscribe here to receive an email when a new monthly congenital adrenal hyperplasia update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).